RxDoctor Payments DataLook up a doctor →

Shayla Sanders

Family · Kansas City, MONPI 1841607900

Payments from drug & device makers

$305,763in general payments, 2019–2025

Across 636 payments — averaging $480.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$223K
  • Lilly USA, LLC$26K
  • GSK$21K
  • AbbVie$20K
  • Sanofi$10K
  • Sobi, Inc$2K
  • plus $3K from 9 others

What the payments were for

  • Consulting fees$6,5032%
  • Speaking & faculty fees$212,76370%
  • Travel & lodging$69,04123%
  • Food & beverage$17,1546%
  • Education$3020%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)293$223,159
Lilly USA, LLC66$26,035
GSK74$21,117
AbbVie105$20,483
Sanofi24$10,007
Sobi, Inc5$1,677
Novartis9$1,406
Johnson & Johnson21$669
Mallinckrodt Hospital Products Inc.7$375
AstraZeneca(2 entities)7$331
ANI Pharmaceuticals, Inc.6$195
UCB, Inc.8$138
Pfizer8$117
Boehringer Ingelheim2$39
Radius Health, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$305,763 in reported general payments places this provider in the 95th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$65,449
Medicare patients
14
Services billed
615

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib74$506,341
Cimzia (2 Pack)Certolizumab Pegol41$269,208
OtezlaApremilast47$254,355
Humira(Cf) PenAdalimumab24$219,680
Skyrizi PenRisankizumab-Rzaa11$212,521
Taltz Autoinjector (2 Pack)Ixekizumab14$190,538
Enbrel SureclickEtanercept24$178,862
RemicadeInfliximab13$127,938
Actemra ActpenTocilizumab13$48,327
Hydroxychloroquine Sulfate306$7,956
Colchicine102$6,607
MethotrexateMethotrexate Sodium379$5,226
Gabapentin166$3,497
Allopurinol314$2,799
Duloxetine Hcl177$2,628

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$20,483$506,34174 claims
UCB, Inc.Cimzia (2 Pack)$138$269,20841 claims
AmgenOtezla$223,159$254,35547 claims
Johnson & JohnsonRemicade$669$127,93813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,812 family providers in Missouri.

Other family in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →